We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

15 hedge funds and large institutions have $261K invested in Ensysce Biosciences in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.43% less ownership

Funds ownership: 13.84% → 13.41% (-0.43%)

12% less funds holding

Funds holding: 17 → 15 (-2)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

43% less capital invested

Capital invested by funds: $461K → $261K (-$200K)

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$36.4K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$32.8K
3
XT
XTX Topco
Cayman Islands
+$15.4K
4
Jane Street
Jane Street
New York
+$8.61K
5
VF
Virtu Financial
New York
+$8.44K

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$90.6K
2
FPI
Financial Plan Inc
Washington
-$22.1K
3
HF
HRT Financial
New York
-$22K
4
TSS
Two Sigma Securities
New York
-$19.9K
5
WN
Williams & Novak
California
-$16.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$80.6K – – –
PA
2
Perceptive Advisors
New York
$46.7K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$39.8K +$32.8K +51,790 +234%
Citadel Advisors
4
Citadel Advisors
Florida
$30.9K +$36.4K +57,363 New
XT
5
XTX Topco
Cayman Islands
$13.1K +$15.4K +24,363 New
VFT
6
Vanguard Fiduciary Trust
Pennsylvania
$12.9K +$15.1K +23,854 New
Jane Street
7
Jane Street
New York
$7.31K +$8.61K +13,570 New
TIAM2
8
Tru Independence Asset Management 2
Oregon
$7K +$634 +1,000 +8%
VF
9
Virtu Financial
New York
$7K +$8.44K +13,313 New
VCM
10
Vanguard Capital Management
Pennsylvania
$6.93K +$8.15K +12,854 New
UBS Group
11
UBS Group
Switzerland
$4.73K +$5.51K +8,691 +8,691%
TRCT
12
Tower Research Capital (TRC)
New York
$3.28K +$491 +775 +15%
FIA
13
FNY Investment Advisers
New York
$1K – – –
SS
14
SBI Securities
Japan
$262 +$41 +65 +15%
BlackRock
15
BlackRock
New York
$35 – – –
DS
16
DRW Securities
Illinois
– -$90.6K -98,481 Closed
HF
17
HRT Financial
New York
– -$22K -24,491 Closed
FPI
18
Financial Plan Inc
Washington
– -$22.1K -24,000 Closed
TSS
19
Two Sigma Securities
New York
– -$19.9K -21,605 Closed
WN
20
Williams & Novak
California
– -$16.4K -17,850 Closed
Bank of America
21
Bank of America
North Carolina
– -$66 -72 Closed
Jones Financial Companies
22
Jones Financial Companies
Missouri
– -$38 -41 Closed

ENSC Hedge Fund Activity: Q1 2026 in Review

15 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q1 2026, worth a combined $261K — down 43% from $461K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ENSC and 6 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 5 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.4K. The largest seller was DRW Securities, exiting entirely with an estimated $90.6K sold.

  • 15 institutional investors held Ensysce Biosciences (ENSC) as of Q1 2026, down from 17 in Q4 2025.
  • Funds reported $261K of Ensysce Biosciences stock for Q1 2026, down 43% quarter-over-quarter.
  • 6 funds opened new Ensysce Biosciences positions in Q1 2026 and 7 closed out, a net change of -1 holder.
  • The largest Ensysce Biosciences buyer in Q1 2026 was Citadel Advisors, an estimated $36.4K added.
  • The largest Ensysce Biosciences seller in Q1 2026 was DRW Securities, an estimated $90.6K sold.

Based on aggregated 13F filings for Q1 2026.